Glycaemic control influences the relationship between plasma PCSK9 and LDL cholesterol in type 1 diabetes

被引:20
作者
Laugier-Robiolle, Stephanie [1 ,2 ]
Verges, Bruno [3 ]
Le Bras, Maelle [4 ]
Gand, Elise [1 ,2 ]
Bouillet, Benjamin [3 ]
Saulnier, Pierre-Jean [5 ]
Le May, Cedric [6 ]
Pichelin, Matthieu [7 ]
Marechaud, Richard [1 ,2 ]
Petit, Jean-Michel [3 ]
Hadjadj, Samy [1 ,2 ,5 ,8 ]
Cariou, Bertrand [7 ]
机构
[1] CHU Poitiers, Endocrinol Diabetol, Poitiers, France
[2] CHU Poitiers, CIC1402, Poitiers, France
[3] Univ Bourgogne, Dept Endocrinol, INSERM, CRI 866,CHU Dijon, Dijon, France
[4] CHU Nantes, Inst Thorax, Dept Endocrinol, Nantes, France
[5] INSERM, CIC1402, Poitiers, France
[6] Univ Nantes, Inst Thorax, INSERM, CNRS, Nantes, France
[7] Univ Nantes, CHU Nantes, Dept Endocrinol, Inst Thorax,INSERM,CNRS, Nantes, France
[8] Univ Poitiers, UFR Med Pharm, Poitiers, France
关键词
dyslipidaemia; lipid-lowering therapy; type; 1; diabetes; SUBTILISIN/KEXIN TYPE 9; CARDIOVASCULAR-DISEASE; ASSOCIATION; EXPRESSION; INSULIN;
D O I
10.1111/dom.12819
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Pro-protein convertase subtilisin/kexin type 9 (PCSK9) is a critical regulator of LDL cholesterol metabolism. Little is known, however, about the regulation of PCSK9 in patients with type 1 diabetes (T1D). In the present study, we aimed to determine the relationship between circulating PCSK9 and metabolic variables in T1D. Plasma PCSK9 levels were measured in 195 people with T1D (mean age 38.8 years, mean diabetes duration 17.2 years, mean glycated haemoglobin [HbA1c] 8.3%), who were free of any lipid-lowering agent. Plasma PCSK9 was positively correlated with LDL cholesterol (P =.0007), triglycerides (P =.004), apolipoprotein B (P =.005), HbA1c (P =.003), systolic (P =.003) and diastolic (P =.001) blood pressure and body mass index (0.02). In multivariate analysis, PCSK9 concentration was independently associated with HbA1c (P =.02) and LDL cholesterol (P =.03). After classifying patients according to HbA1c tertile, the correlation between PCSK9 and LDL cholesterol was only observed in the highest tertile (P =.0006; Rho = 0.43), whereas no correlation was found in the lowest and intermediate tertiles. This study suggests that good glycaemic control abolishes the positive relationship between PCSK9 and LDL cholesterol in patients with T1D; however, the underlying molecular mechanisms remain to be established.
引用
收藏
页码:448 / 451
页数:4
相关论文
共 50 条
  • [31] The relationship between oxLDL, sLOX-1, PCSK9 and carotid intima-media thickness in patients with prediabetes and type 2 diabetes
    Dogan, Zeki
    Senyigit, Abdulhalim
    Durmus, Sinem
    Duvarci, Canan
    Gelisgen, Remise
    Uzun, Hafize
    Tabak, Omur
    SCIENTIFIC REPORTS, 2025, 15 (01):
  • [32] The relationship between glycaemic control and heart failure in 83,021 patients with type 2 diabetes
    Lind, M.
    Olsson, M.
    Rosengren, A.
    Svensson, A-M
    Bounias, I.
    Gudbjornsdottir, S.
    DIABETOLOGIA, 2012, 55 (11) : 2946 - 2953
  • [33] Combined intake of glucose-and lipid-lowering medications further elevates plasma levels of PCSK9 in type 2 diabetes patients
    Awadallah, Samir
    Taneera, Jalal
    Mohammed, Abdul Khader
    Unnikannan, Hema
    Sulaiman, Nabil
    DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS, 2020, 14 (06) : 2087 - 2092
  • [34] Correlation Between Circulating PCSK9 Levels and Gestational Diabetes Mellitus in a Chinese Population
    Wu, Yiming
    Shi, Jie
    Su, Qing
    Yang, Zhen
    Qin, Li
    FRONTIERS IN ENDOCRINOLOGY, 2022, 13
  • [35] Relationship Between Low-Density Lipoprotein Cholesterol and Lipoprotein(a) Lowering in Response to PCSK9 Inhibition With Evolocumab
    Shapiro, Michael D.
    Minnier, Jessica
    Tavori, Hagai
    Kassahun, Helina
    Flower, Andrea
    Somaratne, Ransi
    Fazio, Sergio
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2019, 8 (04):
  • [36] Obstetric and perinatal outcomes in pregnancies complicated by Type 1 and Type 2 diabetes: influences of glycaemic control, obesity and social disadvantage
    Murphy, H. R.
    Steel, S. A.
    Roland, J. M.
    Morris, D.
    Ball, V.
    Campbell, P. J.
    Temple, R. C.
    DIABETIC MEDICINE, 2011, 28 (09) : 1060 - 1067
  • [37] Lowering LDL cholesterol by PCSK9 inhibition: a new era of gene silencing, RNA, and alternative therapies
    Paryani, Mitali
    Gupta, Nikita
    Jain, Sanjay Kumar
    Butani, Shital
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2025, : 6597 - 6615
  • [38] Genetic associations between serum low LDL-cholesterol levels and variants in LDLR, APOB, PCSK9 and LDLRAP1 in African populations
    Hayat, Mahtaab
    Kerr, Robyn
    Bentley, Amy R.
    Rotimi, Charles N.
    Raal, Frederick J.
    Ramsay, Michele
    PLOS ONE, 2020, 15 (02):
  • [39] The Relationship between the Plasma PCSK9 Levels and Platelet Indices in Patients with Stable Coronary Artery Disease
    Li, Sha
    Zhu, Cheng-Gang
    Guo, Yuan-Lin
    Xu, Rui-Xia
    Zhang, Yan
    Sun, Jing
    Li, Jian-Jun
    JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, 2015, 22 (01) : 76 - 84
  • [40] Analysis of the association between plasma PCSK9 and Lp(a) in Han Chinese
    Yang, S-H.
    Li, S.
    Zhang, Y.
    Xu, R-X.
    Zhu, C-G.
    Guo, Y-L.
    Wu, N-Q.
    Qing, P.
    Gao, Y.
    Cui, C-J.
    Dong, Q.
    Sun, J.
    Li, J-J.
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2016, 39 (08) : 875 - 883